Dashboard
Manage Tickers

CARMCarisma Therapeutics Inc.

Nasdaq sesenbio.com


$ 1.45 $ -0.23 (-13.77 %)    

Tuesday, 02-Jul-2024 15:58:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 486.52 $ 6.63 (1.38 %)
DIA $ 393.25 $ 1.83 (0.47 %)
SPY $ 548.30 $ 2.96 (0.54 %)
TLT $ 90.61 $ 0.70 (0.78 %)
GLD $ 215.57 $ -0.01 (0 %)
$ 1.44
$ 1.56
$ 0.00 x 0
$ 0.00 x 0
$ 1.45 - $ 1.65
$ 0.99 - $ 9.77
1,452,649
na
68.37M
$ 0.08
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 04-01-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-09-2022 03-31-2022 10-Q
10 02-28-2022 12-31-2021 10-K
11 11-08-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
14 03-15-2021 12-31-2020 10-K
15 11-09-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-11-2020 03-31-2020 10-Q
18 03-16-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-10-2019 03-31-2019 10-Q
22 03-01-2019 12-31-2018 10-K
23 11-09-2018 09-30-2018 10-Q
24 08-14-2018 06-30-2018 10-Q
25 05-15-2018 03-31-2018 10-Q
26 04-02-2018 12-31-2017 10-K
27 11-17-2017 09-30-2017 10-Q
28 08-14-2017 06-30-2017 10-Q
29 05-04-2017 03-31-2017 10-Q
30 03-24-2017 12-31-2016 10-K
31 11-14-2016 09-30-2016 10-Q
32 08-12-2016 06-30-2016 10-Q
33 05-05-2016 03-31-2016 10-Q
34 03-25-2016 12-31-2015 10-K
35 11-04-2015 09-30-2015 10-Q
36 08-13-2015 06-30-2015 10-Q
37 04-30-2015 03-31-2015 10-Q
38 03-06-2015 12-31-2014 10-K
39 11-13-2014 09-30-2014 10-Q
40 08-13-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Carisma Therapeutics, On June 26, 2024, In...
07/02/2024 20:47:31

Carisma notified Novartis Pharmaceuticals of its termination of the Manufacturing and Supply Agreement, dated March 1, 2023, re...

why-are-carisma-therapeutics-shares-surging-friday
Why Are Carisma Therapeutics Shares Surgin...
06/28/2024 19:49:25

Carisma Therapeutics Inc. (NASDAQ: CARM) shares are trading higher on Friday following the company's announcement of a sign...

Core News & Articles
Market-Moving News for June 28th
06/28/2024 12:37:11

PTGX: 11% | Protagonist Therapeutics To Join S&P SmallCap 600, Effective Prior To Opening Of Trading On July 3 DJT: 16% | ...

hc-wainwright--co-reiterates-buy-on-carisma-therapeutics-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on CARI...
06/28/2024 11:23:37

HC Wainwright & Co. analyst Mitchell Kapoor reiterates CARISMA Therapeutics (NASDAQ:CARM) with a Buy and maintains $8 pr...

Core News & Articles
Carisma Therapeutics Collaborates With Mod...
06/27/2024 20:32:33

Development Candidate targets Glypican-3 for the treatment of solid tumors, including hepatocellular carcinomaNomination trigge...

in-depth-examination-of-5-analyst-recommendations-for-carisma-therapeutics
In-Depth Examination Of 5 Analyst Recommen...
06/26/2024 18:01:04

hc-wainwright--co-reiterates-buy-on-carisma-therapeutics-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on CARI...
06/26/2024 16:22:25

HC Wainwright & Co. analyst Mitchell Kapoor reiterates CARISMA Therapeutics (NASDAQ:CARM) with a Buy and maintains $8 pr...

carisma-therapeutics-shares-are-trading-higher-after-the-fda-granted-fast-track-designation-for-ct-0525-to-treat-her2-overexpressing-solid-tumors
Carisma Therapeutics shares are trading hi...
06/25/2024 11:39:43

carisma-therapeutics-says-fda-granted-fast-track-designation-for-ct-0525-to-treat-her2-overexpressing-solid-tumors
Carisma Therapeutics Says FDA Granted Fast...
06/25/2024 11:32:38

Initial Phase 1 data expected by year-end 2024

the-analyst-verdict-carisma-therapeutics-in-the-eyes-of-4-experts
The Analyst Verdict: CARISMA Therapeutics ...
05/17/2024 15:01:51

hc-wainwright--co-reiterates-buy-on-carisma-therapeutics-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on CARI...
05/17/2024 14:25:38

HC Wainwright & Co. analyst Mitchell Kapoor reiterates CARISMA Therapeutics (NASDAQ:CARM) with a Buy and maintains $8 pr...

carisma-therapeutics-doses-first-patient-in-phase-1-clinical-trial-of-ct-0525-a-novel-her2-targeting-car-monocyte
Carisma Therapeutics Doses First Patient I...
05/16/2024 11:43:50

CT-0525 is the first CAR-Monocyte to be evaluated in humans in the solid tumor setting Initial data expected by year-end 2024

hc-wainwright--co-maintains-buy-on-carisma-therapeutics-lowers-price-target-to-8
HC Wainwright & Co. Maintains Buy on CARIS...
05/10/2024 11:46:46

HC Wainwright & Co. analyst Mitchell Kapoor maintains CARISMA Therapeutics (NASDAQ:CARM) with a Buy and lowers the price...

carisma-therapeutics-says-cash-and-equivalents-of-565m-expected-to-fund-company-into-q3-of-2025
Carisma Therapeutics Says Cash And Equival...
05/09/2024 11:50:33

carisma-therapeutics-q1-2024-gaap-eps-046-misses-043-estimate
CARISMA Therapeutics Q1 2024 GAAP EPS $(0....
05/09/2024 11:49:45

CARISMA Therapeutics (NASDAQ:CARM) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate o...

carisma-therapeutics-announced-new-data-demonstrating-preclinical-proof-of-concept-using-engineered-anti-fibrotic-macrophages-for-the-treatment-of-liver-fibrosis-the-data-was-presented-at-the-american-society-of-gene-and-cell-therapy-annual-meeting
Carisma Therapeutics Announced New Data De...
05/08/2024 11:47:54

carisma-therapeutics-to-present-new-data-at-asgct-annual-meeting
Carisma Therapeutics To Present New Data A...
04/22/2024 20:42:13

Preclinical data highlights the potential of engineered macrophage cell therapy as a treatment for liver and lung fibrosisNovel...

btig-initiates-coverage-on-carisma-therapeutics-with-buy-rating-announces-price-target-of-6
BTIG Initiates Coverage On CARISMA Therape...
04/11/2024 16:19:24

BTIG analyst Justin Zelin initiates coverage on CARISMA Therapeutics (NASDAQ:CARM) with a Buy rating and announces Price Tar...

hc-wainwright--co-maintains-buy-on-carisma-therapeutics-lowers-price-target-to-9
HC Wainwright & Co. Maintains Buy on CARIS...
04/02/2024 12:51:54

HC Wainwright & Co. analyst Mitchell Kapoor maintains CARISMA Therapeutics (NASDAQ:CARM) with a Buy and lowers the price...

carisma-therapeutics-q4-eps-052-beats-055-estimate-sales-429m-beat-290m-estimate
CARISMA Therapeutics Q4 EPS $(0.52) Beats ...
04/01/2024 14:05:13

CARISMA Therapeutics (NASDAQ:CARM) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)